Quantcast
Last updated on April 18, 2014 at 16:07 EDT

Latest ondansetron Stories

2013-09-03 08:28:05

NEW YORK, Sept. 3, 2013 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("ITI" or the "Company"), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, announced that it completed a private placement of approximately 18.9 million shares of its common stock to new and existing investors that resulted in gross proceeds of approximately $60 million to the Company, including approximately $15.3 million in bridge notes that converted into common stock...

2013-08-29 12:26:09

Product Line Momentum is Building FRANKLIN LAKES, N.J., Aug. 29, 2013 /PRNewswire/ -- BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that the U.S. Food and Drug Administration (FDA) has approved the third drug to be offered in the new BD Simplist(TM) line of ready-to-administer prefilled generic injectables. The third BD Simplist product to launch is Ondansetron Injection, USP 4mg/2mL (2mg/mL),...

2013-08-28 12:23:31

Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of Alexza Pharmaceuticals (NASDAQ:ALXA), a California-based pharmaceutical company developing drugs for the acute treatment of central nervous system conditions, including agitation and acute repetitive seizures. LONDON, Aug. 28, 2013 /PRNewswire/ -- Edison has recently published a comprehensive report examining the investment merits of Alexza Pharmaceuticals, which...

2013-07-30 08:34:45

Alexza's Partner Ferrer Records First Product Sales in Germany MOUNTAIN VIEW, Calif., July 30, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that the company's commercial partner Grupo Ferrer Internacional, S.A. has initiated sales of ADASUVE(®) inhalation powder, pre-dispensed (Staccato(®) Loxapine) in the European Union ("EU"). ADASUVE is now available in Germany. The first sale and shipment of product by Ferrer triggers a $1.25 million...

2013-07-01 16:26:33

Phase IIB Study Evaluating Twelve Weeks of Continuous Dosing With NBI-98854 SAN DIEGO, July 1, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed recruitment in the Phase IIb clinical trial (Kinect Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The final subject will randomize this week. The design of this twelve-week Phase IIb study is a randomized, parallel, double-blind, placebo-controlled...

2013-06-21 23:01:55

Johnson & Johnson is appealing the $1.2 billion fine issued by an Arkansas court over off-label marketing claims the company supposedly made regarding its antipsychotic drug Risperdal. However, a large number of Arkansas lawmakers are supporting the fine, and Parker Waichman LLP applauds their efforts as it continues to offer free legal advice to patients who took Risperdal, which has been associated with side effects such as male breast enlargement (gynecomastia). New York, NY (PRWEB)...

2013-05-08 08:31:01

Call Scheduled Today for 9:00 a.m. Eastern Time MOUNTAIN VIEW, Calif., May 8, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) announced today that they have entered into an exclusive U.S. license and supply agreement with Teva Pharmaceutical Industries Ltd (NYSE: TEVA) for ADASUVE(®) (Staccato(®) loxapine). Alexza will be hosting a conference call to discuss this transaction at 9:00 a.m. Eastern Time. Conference Call InformationAnalysts and investors can...

2013-05-08 08:30:57

Adasuve® (loxapine) inhalation powder is approved in the U.S. for the acute treatment of agitation associated with schizophrenia and bipolar disorder NORTH WALES, Pa. and MOUNTAIN VIEW, Calif., May 8, 2013 /PRNewswire/ -- Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: TEVA), and Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) announced today that the companies have entered into an exclusive U.S. license and supply agreement for ADASUVE...

2013-04-18 20:25:00

CHARLOTTESVILLE, Va., April 18, 2013 /PRNewswire/ -- ADial Pharmaceuticals, LLC ("ADial"), announced today that the U.S. Food and Drug Administration ("FDA") has agreed to allow ADial to move forward with its plan to initiate Phase III trials of AD04 as a treatment for alcohol use disorder ("AUD") in certain targeted genotypes population only. Patients will initially be screened for the targeted genotypes and only those with one or more of the targeted genotypes will be enrolled in the trial....

2013-04-16 12:26:32

CHARLESTON, S.C., April 16, 2013 /PRNewswire/ -- Charleston Laboratories, Inc, an emerging specialty pharmaceutical company focused on the research and development of novel pain products that prevent or significantly reduce nausea and vomiting related to opioid analgesics and other pain associated disease states, announced today the U.S. Food and Drug Administration has granted its request for a Pre-IND meeting to discuss the proposed Investigational New Drug, CL-H1T, as a novel treatment for...